Haleon PLC traded at 338.80 this Tuesday September 15th, decreasing 3.40 or 0.99 percent since the previous trading session. Looking back, over the last four weeks, Haleon lost 3.26 percent. Over the last 12 months, its price fell by 0.26 percent. Looking ahead, we forecast Haleon PLC to be priced at 327.49 by the end of this quarter and at 309.27 in one year, according to Trading Economics global macro models projections and analysts expectations.
Haleon plc is a consumer healthcare company. The Company''s product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company''s digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.